id: NEW:lsd_assisted_therapy_to_alcohol_use_disorder
name: LSD-Assisted Therapy â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:lsd_assisted_therapy
  node_name: LSD-Assisted Therapy
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: LSD administered in controlled therapeutic setting under clinical supervision'
- 'Step 2: Psychedelic experience facilitates introspection and emotional processing related to alcohol
  dependence'
- 'Step 3: Therapeutic integration sessions help consolidate insights and behavioral change'
- 'Step 4: Enhanced likelihood of achieving abstinence or substantial reduction in drinking'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: 'Dakota J. Sicignano et al. 2023. "The impact of psychedelics on patients with alcohol
    use disorder: a systematic review with meta-analysis." https://doi.org/10.1080/03007995.2023.2296968'
  supporting_citations:
  - LSD trial 1 (1966-1970 era)
  - LSD trial 2 (1966-1970 era)
  - LSD trial 3 (1966-1970 era)
  doi: 10.1080/03007995.2023.2296968
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'In randomized, double-blind, placebo-controlled trials specifically examining LSD, the odds
  of achieving abstinence or substantial reduction in drinking were 1.99 times higher with LSD compared
  to placebo. When expanded to include 5 controlled trials without strict blinding requirements, OR was
  1.79 (95% CI: 1.36-2.34).'
quantitative_effects:
  effect_size:
    value: 1.99
    type: odds_ratio
    ci_lower: 1.1
    ci_upper: 3.61
moderators:
- name: blinding_and_placebo_control
  direction: strengthens
  strength: moderate
  description: 'Relaxing inclusion to include non-double-blind trials increased sample (n=5) but showed
    similar effect (OR 1.79, 95% CI: 1.36-2.34)'
structural_competency:
  equity_implications: The scheduling of LSD as a controlled substance with no accepted medical use has
    created decades-long barriers to researching this potentially effective treatment. This regulatory
    structure disproportionately affects populations with limited access to emerging treatments and clinical
    trials. Policy reform regarding psychedelic scheduling is a structural determinant of treatment access.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.295530'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
